Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 12;83:104217. doi: 10.1016/j.ebiom.2022.104217

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Author(s)

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

(a) Comparison of GMCs of anti-RBD IgG concentrations for formulations C and B in the Phase-1/2 study vs formulation E in the Phase- 2 study. The GMCs on Day 0 (pre-vaccination) and Day 42 (post-two-dose vaccination) are shown in the figure. Formulation E induced a stronger anti-RBD IgG response than did formulations C and B on Day 42 compared to that on Day 0. The GMCs are shown at the top of the respective columns, and the 95% confidence intervals are shown as two-sided bars.

RBD, receptor-binding domain; GMC, geometric mean concentration; IgG, immunoglobulin G.

(b) Comparison of nAb titres determined by the PNA method against PSV mimicking the ancestral Wuhan strain of SARS-COV-2 for formulations C and B in the Phase- 1/2 study vs formulation E in the Phase- 2 study. The GMTs on Day 0 (pre-vaccination) and Day 42 (post-two-dose vaccination) are shown in the figure. Formulation E induced high NT50 compared to that by formulations C and B tested using the PNA method. GMTs are shown at the top of the respective columns and the 95% confidence interval is shown as two-sided bars.

PNA, pseudovirus neutralisation assay; PSV, pseudovirus; HCS, high-content screening; GMT, geometric mean titre; NT, neutralising titre.

(c) Comparison of nAb titres determined by the MNA method against the ancestral Wuhan strain of SARS-COV-2 for formulations C and B in the Phase- 1/2 study vs formulation E in the Phase- 2 study. GMTs on Day 0 (pre-vaccination) and Days 56 or 42 (post-two-dose vaccination) are shown in the figure. Formulation E induced a very high NT50 compared to that by formulations C and B tested using the MNA method. GMTs are shown at the top of the respective columns and the 95% confidence interval is shown as two-sided bars.

nAb, neutralising antibody; MNA, micro neutralisation assay; HCS, high-content screening; GMT, geometric mean titre.

(d) Comparison of nAb titres determined by the PNA method against PSV mimicking the ancestral Wuhan strain of SARS-COV-2 for formulations C and B in the Phase-1/2 study vs formulation E in the Phase-2 study. The GMTs of MNA were measured for the beta and delta strains and compared with those for the ancestral Wuhan strain on serum samples of Day 42 in a subset of 20 subjects.

MNT, microneutralisation test; GMT, geometric mean titre; PNA, pseudovirus neutralisation assay.

(a) Comparison of GMCs of anti-RBD IgG concentrations for formulations C and B in the Phase-1/2 study vs formulation E in the Phase- 2 study. The GMCs on Day 0 (pre-vaccination) and Day 42 (post-two-dose vaccination) are shown in the figure. Formulation E induced a stronger anti-RBD IgG response than did formulations C and B on Day 42 compared to that on Day 0. The GMCs are shown at the top of the respective columns, and the 95% confidence intervals are shown as two-sided bars.

RBD, receptor-binding domain; GMC, geometric mean concentration; IgG, immunoglobulin G.

(b) Comparison of nAb titres determined by the PNA method against PSV mimicking the ancestral Wuhan strain of SARS-COV-2 for formulations C and B in the Phase- 1/2 study vs formulation E in the Phase- 2 study. The GMTs on Day 0 (pre-vaccination) and Day 42 (post-two-dose vaccination) are shown in the figure. Formulation E induced high NT50 compared to that by formulations C and B tested using the PNA method. GMTs are shown at the top of the respective columns and the 95% confidence interval is shown as two-sided bars.

PNA, pseudovirus neutralisation assay; PSV, pseudovirus; HCS, high-content screening; GMT, geometric mean titre; NT, neutralising titre.

(c) Comparison of nAb titres determined by the MNA method against the ancestral Wuhan strain of SARS-COV-2 for formulations C and B in the Phase- 1/2 study vs formulation E in the Phase- 2 study. GMTs on Day 0 (pre-vaccination) and Days 56 or 42 (post-two-dose vaccination) are shown in the figure. Formulation E induced a very high NT50 compared to that by formulations C and B tested using the MNA method. GMTs are shown at the top of the respective columns and the 95% confidence interval is shown as two-sided bars.

nAb, neutralising antibody; MNA, micro neutralisation assay; HCS, high-content screening; GMT, geometric mean titre.

(d) Comparison of nAb titres determined by the PNA method against PSV mimicking the ancestral Wuhan strain of SARS-COV-2 for formulations C and B in the Phase-1/2 study vs formulation E in the Phase-2 study. The GMTs of MNA were measured for the beta and delta strains and compared with those for the ancestral Wuhan strain on serum samples of Day 42 in a subset of 20 subjects.

MNT, microneutralisation test; GMT, geometric mean titre; PNA, pseudovirus neutralisation assay.